This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TSC2 | |
|---|---|
| Name | TSC2 |
| Other names | tuberin |
| Location | Chromosome 16p13.3 |
| Product | Tuberin protein |
| Uniprot | P49815 |
| Omim | 191092 |
TSC2
TSC2 encodes tuberin, a large evolutionarily conserved protein that forms a key suppressor complex regulating cell growth and nutrient sensing. Discovered through positional cloning in studies of familial hamartomatous syndromes, tuberin interacts with TSC1, integrates signals from PI3K/AKT pathway, AMP-activated protein kinase, and Rheb GTPase, and is implicated in a multisystem disorder with neurological, dermatological, renal, and pulmonary manifestations. Research on tuberin spans molecular cell biology, clinical genetics, and translational pharmacology across academic centers such as Harvard Medical School, Massachusetts General Hospital, University of Cambridge, Johns Hopkins University, and institutes like the Howard Hughes Medical Institute.
Tuberin was identified in linkage studies of familial cortical dysplasia and benign tumor syndromes involving investigators from National Institutes of Health and University of California, San Francisco. The protein acts with hamartin to form a functional unit that restrains mTORC1 signaling downstream of growth factors such as insulin and epidermal growth factor while responding to energy cues from LKB1-AMPK. Mutations in the gene produce a pleiotropic phenotype observed by clinicians in centers like Mayo Clinic and Great Ormond Street Hospital.
The gene maps to 16p13.3 and was cloned following linkage to loci implicated by pedigrees described by investigators affiliated with Children's Hospital Boston and University College London. TSC2 spans multiple exons encoding a ~180 kDa protein with an evolutionarily conserved C-terminal GTPase-activating protein (GAP) domain that acts on Rheb (Ras homolog enriched in brain). The N-terminal region mediates interaction with hamartin, whose gene, discovered independently by teams at Stanford University and University of Toronto, is required for complex stability. Post-translational modifications include phosphorylation by AKT1, phosphorylation by AMPK, and ubiquitination pathways characterized in studies from Cold Spring Harbor Laboratory and EMBL. Structural insights have been informed by cryo-EM and X-ray crystallography efforts carried out at facilities such as European Synchrotron Radiation Facility.
Tuberin functions as a GAP for Rheb, thereby inhibiting mammalian target of rapamycin complex 1 (mTORC1), a central node described in landmark publications from Dana-Farber Cancer Institute and Salk Institute. Through interaction with TSC1, tuberin senses signals from receptor tyrosine kinases including EGFR and PDGFR, nutrient sensors such as v-ATPase-regulated amino acid signaling described in studies at Max Planck Institute, and energy status via LKB1-AMPK. Phosphorylation by AKT1 downstream of PI3K attenuates GAP activity, linking tuberin to oncogenic signaling characterized in work at Cold Spring Harbor Laboratory and Memorial Sloan Kettering Cancer Center. The complex also cross-talks with autophagy regulators investigated by teams at Karolinska Institutet and Institute of Cancer Research (London).
Germline loss-of-function variants cause tuberous sclerosis complex (TSC), a multisystem disorder first clinically cataloged by clinicians at Harvard and Great Ormond Street Hospital. Patients develop cortical tubers, subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas, cardiac rhabdomyomas, pulmonary lymphangioleiomyomatosis, and skin findings like hypomelanotic macules recognized in case series from Johns Hopkins Hospital. Neuropsychiatric features include epilepsy, intellectual disability, and autism spectrum disorder; multidisciplinary care models have been advanced at Cleveland Clinic and Boston Children's Hospital. Somatic second-hit mutations, described in tumor studies from UCSF and NIH Clinical Center, explain focal lesion formation under Knudson-like hypotheses that echo oncologic paradigms at Memorial Sloan Kettering Cancer Center.
Diagnostic criteria integrate clinical findings codified by consensus panels convened at institutions like European Reference Network and American Academy of Neurology with molecular testing using sequencing approaches developed at Broad Institute and clinical labs accredited by College of American Pathologists. Testing strategies include germline sequencing, deletion/duplication analysis, and mosaicism detection through deep sequencing deployed at centers such as Mayo Clinic Laboratories. Prenatal and preimplantation genetic diagnosis services are provided by specialized units at Mount Sinai Health System and UCSF Medical Center for families with pathogenic variants cataloged in databases curated by ClinVar and OMIM.
mTORC1 inhibitors, pioneered in clinical trials led by teams at National Cancer Institute and UChicago Medicine, form the backbone of targeted therapy for TSC-related tumors; agents include rapamycin (sirolimus) and everolimus with approvals influenced by registrational studies from Novartis and cooperative groups. Adjunctive strategies target upstream signaling nodes such as PI3K and AKT1, while AMPK activators and autophagy modulators have been explored in translational programs at Imperial College London and Stanford University. Symptomatic management for epilepsy uses antiepileptics evaluated in multicenter trials coordinated by European Society for Paediatric Neurology and surgical approaches reported from Mayo Clinic and Johns Hopkins for refractory cases.
Ongoing research employs genetically engineered mouse models developed at The Jackson Laboratory and conditional knockouts produced at Cold Spring Harbor Laboratory to dissect neurodevelopmental effects. Human induced pluripotent stem cell models generated by teams at Salk Institute and organoid systems cultivated at Weizmann Institute enable study of cortical tuberogenesis and drug screening. Single-cell transcriptomics from consortia such as Human Cell Atlas and spatial proteomics at Broad Institute are mapping lesion heterogeneity. Gene therapy, CRISPR-based correction developed at MIT and antisense oligonucleotide strategies from Biogen-linked collaborations represent translational paths under investigation.
Category:Genes on human chromosome 16 Category:Oncogenes and tumor suppressors Category:Signal transduction proteins